Syros Pharmaceuticals Shares Plummet Premarket
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with ...
Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and ...
With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...
Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The company’s shares closed yesterday at $2.73. Nadeau covers the ...
The Kia Syros is expected to debut sometime in the coming weeks. Its market launch is part of the “Kia 2.0 Strategy” for the ...
Renamed newcomer will be positioned between the Sonet and Seltos and go on-sale in early 2025 in India with South African market availability unknown at present.
Shares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, tamibarotene, for treating higher-risk myelodysplastic syndrome (HR-MDS) ...
The upcoming Kia Syros will most likely be positioned between Sonet and Seltos, therefore, potentially creating a new segment ...
Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback